Immune checkpoint inhibitor-induced diabetes mellitus in metastatic NSCLC: a case report with extended follow-up and management considerations - Takeaways - MDSpire

Immune checkpoint inhibitor-induced diabetes mellitus in metastatic NSCLC: a case report with extended follow-up and management considerations

  • By

  • Daniele Nova

  • Gabriele Giuseppe Pagliari

  • Sara Mambrito

  • Diego Luigi Cortinovis

  • Stefania Canova

  • July 17, 2026

Share

  • 1

    Immune checkpoint inhibitors can induce diabetes mellitus (ICI-DM), a rare but severe endocrine adverse event in lung cancer patients.

  • 2

    ICI-DM is characterized by rapid destruction of insulin-producing pancreatic β-cells, leading to irreversible insulin dependence.

  • 3

    Lung cancer patients account for 20-30% of reported ICI-DM cases, reflecting the use of PD-1/PD-L1 inhibitors in thoracic oncology.

  • 4

    The case study reports a 72-year-old male with metastatic lung adenocarcinoma who developed severe ICI-DM after treatment with pembrolizumab.

  • 5

    Long-term follow-up showed sustained oncological disease control despite the interruption of immunotherapy due to ICI-DM.

Original Source(s)

Immune checkpoint inhibitor-induced diabetes mellitus in metastatic NSCLC: a case report with extended follow-up and management considerations

  • by Daniele Nova, Gabriele Giuseppe Pagliari, Sara Mambrito, Diego Luigi Cortinovis, Stefania Canova

  • July 17, 2026

Related Content

Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report

First-line penpulimab combined with anlotinib achieves complete response in an elderly patient with occult lung squamous cell carcinoma: a case report

Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications